Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Advertisements

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Circ Cardiovasc Qual Outcomes

by Adam J. Singer, Robert H

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Circ Arrhythm Electrophysiol

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

Complexities of Genetic Testing in Familial Dilated Cardiomyopathy

Impact of Genetic Variants in Human Scavenger Receptor Class B Type I (SCARB1) on Plasma Lipid TraitsCLINICAL PERSPECTIVE by Vipavee Niemsiri, Xingbin.

Functional Recovery in Aged and Young Rats After Embolic Stroke

Sex-Related Differences in Fractional Flow Reserve–Guided Treatment

by Jenny K. Rinehart, Rena D. Singleton, John C. Adair, Joseph R

Value-Based Hypothesis Testing for Cardiac Device Clinical Trials

Circ Cardiovasc Qual Outcomes

Optima DES system: The stent has multiple grooves (reservoirs) on its abluminal surface into which the drug is loaded. Optima DES system: The stent has.

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Site Selection and Performance in Clinical Trials

Circ Cardiovasc Qual Outcomes

So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

Behavior and Biology: The Basic Sciences for AHA Action

Physician and Patient Influences on Provider Performance

Low-Flow Mediated Constriction is Endothelium-Dependent

Arterioscler Thromb Vasc Biol

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Relative Distributions

Circ Cardiovasc Qual Outcomes

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Effect of Provider Volume on the Accuracy of Hospital Report Cards

New Frontiers in Cardiology

Circ Cardiovasc Imaging

Iatrogenic Adverse Events in the Coronary Care Unit

Virtual Reality in Stroke Rehabilitation

Arterioscler Thromb Vasc Biol

Box plot showing percentage change in early diastolic pulsed-Doppler mitral inflow (E)/early diastolic tissue Doppler velocity (E´) from pre– to post–balloon.

Circ Cardiovasc Qual Outcomes

by Parag C. Patel, Colby R. Ayers, Sabina A

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

Mathematical representation of Bayes theorem.

Circ Cardiovasc Qual Outcomes

Evidence for Shear Stress–Mediated Dilation of the Internal Carotid Artery in HumansNovelty and Significance by Howard H. Carter, Ceri L. Atkinson, Ilkka.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Fractional Flow Reserve Returns to Its Origins

Copyright © 2016 Elsevier Inc. All rights reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Copyright © 2004 The McGraw-Hill Companies, Inc. All rights reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Copyright © 2013 Elsevier Inc. All rights reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Copyright © 2004 The McGraw-Hill Companies, Inc. All rights reserved.

Copyright © 2004 The McGraw-Hill Companies, Inc. All rights reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Copyright © 2013 Elsevier Inc. All rights reserved.

Modeling Functionality with Use Cases

Copyright © 2012, Elsevier Inc. All rights Reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Chapter 103 Long-Term Care: The Global Impact

Copyright © 2013 Elsevier Inc. All rights reserved.

Copyright © 2012, Elsevier Inc. All rights Reserved.

Chapter 15 Contraception

Copyright © 2013 Elsevier Inc. All rights reserved.

Presentation transcript:

Circ Cardiovasc Interv Impact of Introducer Sheath Coating on Endothelial Function in Humans After Transradial Coronary ProceduresCLINICAL PERSPECTIVE by Ellen A. Dawson, Sudhir Rathore, N. Timothy Cable, D. Jay Wright, John L. Morris, and Daniel J. Green Circ Cardiovasc Interv Volume 3(2):148-156 April 20, 2010 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Changes in FMD (%) in the catheterized and noncatheterized control arms before and after procedure. Figure 1. Changes in FMD (%) in the catheterized and noncatheterized control arms before and after procedure. Top panel shows coated sheath, and bottom shows uncoated sheath. Data are presented as mean±SD. *Significantly different from pre P<0.05. Ellen A. Dawson et al. Circ Cardiovasc Interv. 2010;3:148-156 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Changes in GTN (%) in the catheterized and noncatheterized control arms before and after procedure. Figure 2. Changes in GTN (%) in the catheterized and noncatheterized control arms before and after procedure. Top panel shows coated sheath, and bottom shows uncoated sheath. Data are presented as mean±SD. *Significantly different from pre P<0.05. Ellen A. Dawson et al. Circ Cardiovasc Interv. 2010;3:148-156 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Changes in FMD (%) in the catheterized and noncatheterized arms post and recov. Figure 3. Changes in FMD (%) in the catheterized and noncatheterized arms post and recov. Top panel shows coated sheath data, and bottom shows uncoated sheath data. Data are presented as mean±SD. *Significantly different from pre P<0.05. Ellen A. Dawson et al. Circ Cardiovasc Interv. 2010;3:148-156 Copyright © American Heart Association, Inc. All rights reserved.

Figure 4. Changes in GTN (%) in the catheterized and noncatheterized arms post to recov. Figure 4. Changes in GTN (%) in the catheterized and noncatheterized arms post to recov. Top panel shows coated sheath data, and bottom shows uncoated sheath. Data are presented as mean±SD. *Significantly different from pre P<0.05. Ellen A. Dawson et al. Circ Cardiovasc Interv. 2010;3:148-156 Copyright © American Heart Association, Inc. All rights reserved.